LifeMD, Inc.
Close on Oct 19, 2026
- Market cap
- $107.52M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 16, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $47.30M | $-0.16 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | After market close | $50.20M | $-0.20 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 9, 2026 | After market close | $46.90M | $-0.04 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 17, 2025 | After market close | $60.20M | $-0.10 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | After market close | $62.20M | $-0.06 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | After market close | $65.70M | $0.01 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 10, 2025 | After market close | $64.25M | $-0.02 | $0.21 |
| Q4 FY2021 Ended Dec 31, 2021 | Jan 19, 2022 | During market hours | – | – | – |
| Q1 FY2021 Ended Mar 31, 2021 | Apr 1, 2021 | During market hours | – | – | – |
| Q4 FY2020 Ended Dec 31, 2020 | Jan 19, 2021 | After market close | – | – | – |
| Q3 FY2016 Ended Sep 30, 2016 | Oct 12, 2016 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | third quarter of 2026 | -$1.00M to $2.00M | New |
| adjusted EBITDAnon-GAAP | fourth quarter 2026 | $3.00M to $6.00M | New |
| Revenue | full year 2026 | $205.50M to $212.50M | Lowered |
| Revenue | third quarter of 2026 | $48.00M to $51.00M | New |
| revenue | fourth quarter 2026 | $60.00M to $64.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements LifeMD filed with the SEC
Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Second Quarter 2026 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports First Quarter 2026 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team
Executive or director change · Other events · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Third Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17
Regulation FD disclosure · EX-99.1 to Form 8-K
Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
LifeMD Reports Second Quarter 2025 Results
Results of operations · EX-99.1 to Form 8-K
Names COO and Promotes Two Executives
Executive or director change · Other events · EX-99.1 to Form 8-K
LifeMD Reports First Quarter 2025 Results and
Results of operations · EX-99.1 to Form 8-K
LifeMD Acquires Women’s Health Provider Optimal
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Fourth Quarter 2024 Results
Results of operations · EX-99.1 to Form 8-K
Appoints Dr. Calum MacRae to its Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
and Medifast Partner to Offer Transformative Weight Management Solution
Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Appoints William J. Febbo to its Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Inc. Announces Closing of New $40 Million Credit Facility
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Appoints Dr. Joan LaRovere to its Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K